Unfractionated Heparin

Comprehensive Clinical Guide: Unfractionated Heparin (UFH)

1. Introduction and Overview

Unfractionated Heparin (UFH) remains a cornerstone of anticoagulant therapy in modern clinical practice. Despite the emergence of Low-Molecular-Weight Heparins (LMWHs) and Direct Oral Anticoagulants (DOACs), UFH retains a critical role in hospital-based medicine, particularly in settings requiring rapid onset, short half-life, and complete reversibility.

As a naturally occurring glycosaminoglycan, UFH is a heterogeneous mixture of polysaccharide chains with varying molecular weights (ranging from 3,000 to 30,000 Daltons). Its primary utility lies in the prevention and treatment of venous thromboembolism (VTE), the management of acute coronary syndromes (ACS), and as an essential anticoagulant for extracorporeal circulation (e.g., cardiopulmonary bypass).

2. Mechanism of Action: The Molecular Deep-Dive

The anticoagulant effect of UFH is not direct; it functions as a catalytic template.

The Antithrombin III (ATIII) Pathway

UFH exerts its primary effect by binding to Antithrombin III (ATIII), a circulating serine protease inhibitor. The binding of a specific pentasaccharide sequence within the heparin chain to ATIII induces a conformational change in the latter, increasing the rate of inhibition of thrombin (Factor IIa) and Factor Xa by approximately 1,000 to 10,000-fold.

The Thrombin-Heparin-ATIII Ternary Complex

Unlike LMWH, UFH molecules are sufficiently long (at least 18 saccharide units) to bridge the gap between ATIII and thrombin simultaneously. This creates a ternary complex that inactivates thrombin with high efficiency. This unique bridge-forming mechanism is the primary reason why UFH is more effective at inhibiting thrombin than LMWH.

3. Pharmacokinetics and Pharmacodynamics

Understanding the unpredictable kinetics of UFH is essential for safe clinical management.

• Absorption: UFH is not absorbed from the gastrointestinal tract and must be administered via intravenous (IV) or subcutaneous (SC) routes.
• Distribution: UFH is highly protein-bound, primarily to albumin and various plasma proteins. This accounts for the inter-patient variability in anticoagulant response.
• Metabolism: Clearance occurs through two mechanisms:
  1. Saturable mechanism: Rapid, dose-dependent uptake by the reticuloendothelial system (endothelial cells and macrophages).
  2. Non-saturable mechanism: Slower, dose-independent renal excretion.
• Half-life: Dose-dependent. At clinical doses, the half-life is typically 60–90 minutes.

4. Clinical Indications and Dosage Guidelines

UFH dosing is highly protocol-driven. Clinicians must utilize weight-based nomograms to ensure therapeutic efficacy while minimizing bleeding risks.

Primary Indications

1. Venous Thromboembolism (VTE): Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
2. Acute Coronary Syndromes (ACS): Adjunct to antiplatelet therapy for unstable angina and non-ST-elevation myocardial infarction (NSTEMI).
3. Extracorporeal Circuits: Prevention of clotting during hemodialysis and cardiopulmonary bypass.
4. Atrial Fibrillation: Bridging therapy in patients awaiting cardioversion or transition to warfarin.

Standard Weight-Based Nomogram (Example)

• Initial Bolus: 80 units/kg IV push.
• Initial Infusion: 18 units/kg/hour.
• Monitoring: Activated Partial Thromboplastin Time (aPTT) every 6 hours until therapeutic range (usually 1.5–2.5x control) is reached.

5. Contraindications and Risks

The primary risk associated with UFH is hemorrhage. However, specific immunological reactions pose significant morbidity.

Absolute Contraindications

• History of Heparin-Induced Thrombocytopenia (HIT).
• Active major bleeding.
• Severe thrombocytopenia.
• Hypersensitivity to heparin or pork products.

Heparin-Induced Thrombocytopenia (HIT)

HIT is a pro-thrombotic disorder caused by antibodies against the heparin-Platelet Factor 4 (PF4) complex.
* Type I: Non-immune, transient, mild drop in platelets.
* Type II: Immune-mediated, severe, high risk of arterial/venous thrombosis. Requires immediate cessation of all heparin products.

6. Drug Interactions

7. Pregnancy and Lactation

UFH is the preferred anticoagulant in pregnancy.
* Placental Barrier: UFH is a large, highly polar molecule and does not cross the placenta. It is not associated with teratogenicity.
* Lactation: UFH is not excreted in breast milk and is considered safe for breastfeeding mothers.

8. Overdose Management

In the event of life-threatening hemorrhage or supratherapeutic aPTT, the antidote is Protamine Sulfate.
* Mechanism: Protamine is a basic protein that binds to the acidic heparin molecule, forming a stable salt complex that neutralizes heparin’s anticoagulant activity.
* Dosing: 1 mg of protamine neutralizes approximately 100 units of heparin.
* Caution: Administer slowly (over 10 minutes) to avoid hypotension, bradycardia, and anaphylactoid reactions.

9. Frequently Asked Questions (FAQ)

Q1: Why is UFH preferred over LMWH in patients with renal failure?

UFH is primarily cleared by the reticuloendothelial system rather than the kidneys. LMWH relies on renal excretion; therefore, it can accumulate in patients with severe renal impairment (CrCl < 30 mL/min), increasing bleeding risk.

Q2: What is the therapeutic range for aPTT?

Generally, the therapeutic range is 1.5 to 2.5 times the patient's baseline or laboratory control value. However, institutions should calibrate this based on the specific reagents used in their clinical labs.

Q3: How do I manage a patient with suspected HIT?

Stop all heparin products immediately. Do not wait for lab confirmation. Initiate a non-heparin anticoagulant, such as Argatroban or Bivalirudin.

Q4: Can UFH be given subcutaneously?

Yes, but it is typically reserved for prophylaxis (e.g., 5,000 units SC every 8–12 hours). It is not recommended for the treatment of active clots due to erratic absorption.

Q5: Does UFH cause osteoporosis?

Long-term use (usually >3 months) of therapeutic doses of UFH is associated with decreased bone density and potential fractures.

Q6: What is the "Heparin Resistance" phenomenon?

This occurs when a patient requires >35,000 units/day to achieve a therapeutic aPTT. It is often due to low ATIII levels (e.g., in sepsis, DIC, or liver disease).

Q7: How often should I monitor platelets?

In patients receiving therapeutic UFH, a baseline platelet count should be obtained, followed by serial monitoring every 2–3 days, especially between days 5 and 10 of therapy to screen for HIT.

Q8: What if the patient has an allergy to pork?

Heparin is derived from porcine intestinal mucosa. Patients with religious or severe allergic contraindications to porcine products may require alternative anticoagulants like Fondaparinux or Danaparoid.

Q9: Can I mix UFH with other medications?

No. UFH is physically incompatible with many drugs (e.g., aminoglycosides, diazepam). Always use a dedicated IV line or flush thoroughly between administrations.

Q10: Does UFH affect PT/INR?

UFH can cause a mild elevation in the Prothrombin Time (PT/INR), which can complicate the transition to warfarin therapy. Always ensure the INR is measured at a time when the heparin infusion has been held or use chromogenic assays if necessary.

10. Conclusion

Unfractionated Heparin remains an indispensable therapeutic tool in the armamentarium of the modern clinician. Its short half-life and reversibility make it the gold standard in high-stakes clinical scenarios, including cardiovascular surgery and unstable VTE. However, the requirement for frequent laboratory monitoring and the risk of HIT necessitates a rigorous, protocol-based approach to administration. By adhering to weight-based nomograms and maintaining high clinical suspicion for adverse events, practitioners can safely navigate the complexities of heparin therapy.

Disclaimer: This guide is for educational purposes only. Always consult your facility’s specific clinical protocols and local pharmacy policies before administering anticoagulant therapy.